NCT07219615View on ClinicalTrials.gov

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 24, 2025

Primary Completion Date

December 25, 2026

Study Completion Date

April 23, 2027

Conditions
Chronic Spontaneous Urticaria
Interventions
DRUG

Ritlecitinib 50 mg

50 mg Capsule

DRUG

Ritlecitinib 100 mg

100 mg Capsule

DRUG

Placebo - 50 mg

Matching Capsule

DRUG

Placebo - 100 mg

Matching Capsule

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT07219615 - A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | Biotech Hunter | Biotech Hunter